20 results on '"Onori N"'
Search Results
2. Anaphylaxis to dexrazoxane (ICRF-187) following three previous uncomplicated infusions
- Author
-
Leoni, V., Santini, D., Vincenzi, B., Grilli, C., Onori, N., and Tonini, G.
- Published
- 2004
3. The antineoplastic role of bisphosphonates: from basic research to clinical evidence
- Author
-
Santini, D., Gentilucci, U. Vespasiani, Vincenzi, B., Picardi, A., Vasaturo, F., La Cesa, A., Onori, N., Scarpa, S., and Tonini, G.
- Published
- 2003
4. Apelin expression in normal human tissues
- Author
-
Falco, M., Luca, L., Onori, N., Cavallotti, I., Artigiano, F., Esposito, V., Luca, B., Laforgia, V., Groeger, A. M., Antonio De Luca, DE FALCO, Maria, DE LUCA, L., Onori, N., Cavallotti, I., Artigiano, F., Esposito, V., DE LUCA, B., Laforgia, Vincenza, Groeger, A. M., DE LUCA, A., DE FALCO, M, DE LUCA, L, Onori, N, Cavallotti, I, Artigiano, F, Esposito, V, DE LUCA, B, Laforgia, V, Groeger, Am, and DE LUCA, Antonio
- Subjects
Organ Specificity ,Apelin ,Humans ,Intercellular Signaling Peptides and Proteins ,Female ,Tissue Distribution ,Carrier Proteins ,Ligands ,Immunohistochemistry - Abstract
Apelin is an endogenous ligand of the human orphan receptor APJ (orphan G protein-coupled receptor). This peptide is produced through processing from the C-terminal portion in the pre-proprotein consisting of 77 amino acid residues and exists in multiple molecular forms. Although the main physiological functions of apelin have not been clarified yet, it has been demonstrated that apelin partially suppresses cytokine production from mouse spleen and, specifically, induces the promotion of extracellular acidification and inhibition of cAMP production in Chinese hamster ovary cells. Moreover, it is involved in the regulation of blood pressure and blood flow. In this study we have analyzed, by immunohistochemistry, apelin distribution in several human tissues, demonstrating that apelin has a widespread pattern of expression. These results seem to confirm that apelin functions widely in various tissues interacting with its specific receptor APJ.
- Published
- 2002
5. Immunohistochemical study of apelin, the natural ligand of receptor APJ, in a case of AIDS-related cachexia
- Author
-
ESPOSITO V, DE LUCA L, ACANFORA F, ONORI N, LOIACONO L, MONTESARCHIO V, ROSSI M, DE LUCA B, CHIRIANNI A., DE FALCO, MARIA, Esposito, V, DE FALCO, Maria, DE LUCA, L, Acanfora, F, Onori, N, Loiacono, L, Montesarchio, V, Rossi, M, DE LUCA, B, and Chirianni, A.
- Published
- 2002
6. Bilateral irreversible hearing loss associated with the combination of carboplatin and paclitaxel chemotherapy: a unusual side effect
- Author
-
Salvinelli F, Casale M, Vincenzi B, Daniele Santini, Di Peco V, Firrisi L, Onori N, Greco F, and Tonini G
- Subjects
Adult ,Ovarian Neoplasms ,Time Factors ,Treatment Outcome ,Audiometry ,Paclitaxel ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Female ,Hearing Loss ,Carboplatin ,Neoplasm Staging - Abstract
The regimen with paclitaxel and platinum compound (carboplatin or cisplatin) is the standard chemotherapy for patients with advanced ovarian cancer. Ototoxity for carboplatin and paclitaxel alone or combined is rarely observed. We report the case of a 35-year old female with advanced ovarian cancer who developed sudden bilateral sensorineural hearing loss related to paclitaxel and carboplatin based chemotherapy. This uncommon adverse effect of carboplatin and paclitaxel alone or combined is discussed and the literature reviewed. Hearing monitoring should be mandatory to evaluate the real incidence of clinical and sub-clinical hearing modification induced by carboplatin and paclitaxel based chemotherapy.
- Published
- 2003
7. Oxaliplatin may induce cytokine-release syndrome in colorectal cancer patients
- Author
-
Tonini G, Daniele Santini, Vincenzi B, Borzomati D, Dicuonzo G, La Cesa A, Onori N, and Coppola R
- Subjects
colonrectal cancer ,treatment ,complication ,Diarrhea ,Male ,Lung Neoplasms ,Fever ,Organoplatinum Compounds ,Interleukin-6 ,Tumor Necrosis Factor-alpha ,Liver Neoplasms ,Antineoplastic Agents ,Nausea ,Syndrome ,Middle Aged ,Dexamethasone ,Abdominal Pain ,Oxaliplatin ,Cytokines ,Humans ,Female ,Hypotension ,Colorectal Neoplasms ,Aged - Abstract
Oxaliplatin, a third-generation platinum analogue, is a novel compound with proven anti-tumor activity in colorectal cancer. Moreover, oxaliplatin appears to be relatively well tolerated and easy to handle, even on an outpatient basis.Five advanced colorectal cancer patients treated with oxaliplatin-based chemotherapy developed, after the end of oxaliplatin infusion, similar idiosyncratic reactions characterized by chills, high fever, hypotension, abdominal pain, nausea and often diarrhoea. Venous blood for IL-6 and TNF-alpha assessment was drawn just after the beginning of the reaction and 15 and 30 minutes later. After drawing the third venous sample, intravenous dexamethasone (8 mg) was administered and the drawing of other two venous samples was performed (180 and 360 minutes after the beginning of the reaction).TNF-alpha and IL-6 serum concentrations significantly decreased after steroid therapy administration. The decrease of TNF-alpha and IL-6 levels went along with the clinical complete regression of symptoms and signs in all the 5 patients. No statistically significant correlation was found between other laboratory parameters and basal cytokine levels or cytokine decrease after steroid therapy.Our results clearly show that that idiosyncratic reaction observed in colorectal cancer patients after oxaliplatin infusion may be due to a massive release of cytokines such as TNF-alpha and IL-6. Symptom regression following steroid therapy administration went along with significant decrease of cytokines levels, confirming that TNF-alpha and IL-6 play a role in the pathogenesis of this reaction.
- Published
- 2002
8. GABRA2 and alcohol use disorders: no evidence of an association in an Italian case-control study.
- Author
-
Onori N, Turchi C, Solito G, Gesuita R, Buscemi L, and Tagliabracci A
- Published
- 2010
- Full Text
- View/download PDF
9. Effects of indinavir in a preliminary phase I study on dogs with stage III slenic hemangiosarcoma
- Author
-
Spugnini, E. P., Esposito, V., Groeger, A. M., Cassandro, R., Onori, N., Chirianni, A., Alfonso Baldi, Spugnini, Ep, Esposito, V, Groeger, Am, Cassandro, R, Onori, N, Chirianni, A, and Baldi, Alfonso
- Subjects
Hemagiosarcoma ,Dog ,Indinavir - Abstract
HIV protease inhibitors are antiretroviral drugs able to prevent production of infectious particles. It has been shown that these protease inhibitors are able to inhibit cancer-promoted angiogenesis in patients affected by Kaposi's sarcoma. A preliminary phase I study on dogs with stage III splenic hemangiosarcoma was designed in order to evaluate the efficacy and toxicity of the protease inhibitor Indinavir to delay the progression of this advanced neoplasm. The results suggest that Indinavir is potentially beneficial in dogs affected by microscopic residual disease.
10. Prevention of radiotherapy-induced emesis
- Author
-
Tonini G, Vincenzi B, Santini D, La Cesa A, Finolezzi E, Onori N, Rolando M. D'Angelillo, Baldi A, and Trodella L
- Subjects
Clinical Trials as Topic ,Radiotherapy ,Settore MED/36 ,Risk Factors ,Vomiting ,Neoplasms ,Antiemetics ,Humans ,Radiotherapy Dosage ,Radionuclide Imaging ,Settore MED/06 - Abstract
In this minireview the authors examine and discuss the radioprotective compounds and the new combination therapies for the prophylaxis of radiation-induced emesis. Radiation-induced emesis is an important secondary effect of this anticancer treatment and it represents one of the causes of therapy interruption and decay of life quality before the introduction of optimal control of radiation-induced emesis with new antiemetic drugs which ensure the continuance of radiotherapy and avoid time breaks, that could negatively influence the efficacy of anticancer treatment. The incidence, the severity or the latency of radiotherapy-induced nausea and vomiting are correlated both with the treatment features (fractions, total dose, irradiation site) and with the main clinical characteristics of the patients. In contrast to the very extensive literature on the prevention of chemotherapy-induced emesis, relatively few studies about the prevention of nausea and vomiting in patients submitted to radiotherapy have been published. Among antiemetic drugs for the prevention of emesis, benzamides and in particular metoclopramide, are widely used in clinical practice. The introduction of selective 5-HT3 antagonists in clinical practice produced an important improvement in control of chemotherapy induced emesis, but few published studies were aimed at evaluating the efficacy of these drugs in the prophylaxis of nausea and vomiting due to radiation exposure. We herewith present a brief summary of Clinical practice guidelines for the use of antiemetics in anticancer therapy recently published by ASCO (American Society of Clinical Oncology).
11. Allergy Net Anaphylaxis to dexrazoxane (ICRF-187) following three previous uncomplicated infusions.
- Author
-
Leoni, V., Santini, D., Vincenzi, B., Grilli, C., Onori, N., and Tonini, G.
- Subjects
HEPATOTOXICOLOGY ,ANTHRACYCLINES ,THROMBOCYTOPENIA ,RADIOTHERAPY ,MEDICINE ,MEDICAL sciences - Abstract
Dexrazoxane (DEX) is clinically used as an anthracycline-cardioprotective agent and may act by preventing iron based oxygen free-radical damage. The phase I trials indicated that DEX could be safely administered with leukopenia and thrombocytopenia being the dose-limiting toxicities, on a number of different schedules of administration, except in children, in whom the major dose-limiting toxicity is hepatotoxicity. With the extensive use of anthracydine based chemotherapy regimens either alone or in combination with radiation therapy in the management of several malignancies, this uncommon complication should be kept in mind for early detection and successful management.
- Published
- 2004
- Full Text
- View/download PDF
12. Pulse-mediated chemotherapy enhances local control and survival in a spontaneous canine model of primary mucosal melanoma
- Author
-
Emanuele Dragonetti, N Onori, Bruno Vincenzi, Enrico P. Spugnini, Alfonso Baldi, Gennaro Citro, Spugnini, E. P., Dragonetti, E, Vincenzi, B, Onori, N, Citro, G, and Baldi, Alfonso
- Subjects
Oral ,Male ,Cancer Research ,Pathology ,medicine.medical_specialty ,medicine.medical_treatment ,Electrochemotherapy ,Dermatology ,Disease-Free Survival ,Bleomycin ,Dogs ,Medicine ,Animals ,Dog Diseases ,neoplasms ,Melanoma ,Chemotherapy ,Mucous Membrane ,business.industry ,Pulse (signal processing) ,Mucosal melanoma ,Treatment options ,Immunotherapy ,medicine.disease ,Electric Stimulation ,Radiation therapy ,Survival Rate ,Electroporation ,Treatment Outcome ,Oncology ,Pulse Therapy, Drug ,Cancer research ,Female ,Mouth Neoplasms ,business ,Canine model ,Biphasic pulse - Abstract
Mucosal melanomas account for 1% of all malignant melanomas in humans. Treatment options include surgery, chemotherapy, immunotherapy and radiation therapy; however, local recurrence and distant dissemination are still frequent. We treated locally aggressive spontaneous canine oral melanomas that, because of their advanced stage, were not treatable with conventional strategies. A cohort of 10 dogs with oral melanoma was enrolled over a 4-year period. The dogs received two sessions of local bleomycin, followed by the application of trains of biphasic pulses. The treatment was well tolerated and resulted in an overall response rate of 80% with 50% long-term control. Of interest, only one of the dogs died of metastatic disease, and four of the long-term survivors showed a vitiligo-like discoloration at the site of treatment, potentially suggesting a recruitment of the immune system by the therapy. Further studies are needed to characterize this approach and to determine its suitability for head and neck mucosal melanoma. © 2006 Lippincott Williams & Wilkins.
- Published
- 2006
13. Synovial Biomarkers to Detect Chronic Periprosthetic Joint Infection: A Pilot Study to Compare Calprotectin Rapid Test, Calprotectin ELISA Immunoassay and Leukocyte Esterase Test.
- Author
-
Grassi M, Salari P, Farinelli L, D'Anzeo M, Onori N, and Gigante A
- Subjects
- Biomarkers analysis, Carboxylic Ester Hydrolases analysis, Enzyme-Linked Immunosorbent Assay, Humans, Immunoassay, Leukocyte L1 Antigen Complex analysis, Pilot Projects, Sensitivity and Specificity, Synovial Fluid chemistry, Arthritis, Infectious complications, Arthritis, Infectious diagnosis, Arthroplasty, Replacement, Knee adverse effects, Prosthesis-Related Infections diagnosis, Prosthesis-Related Infections etiology
- Abstract
Background: Periprosthetic joint infection (PJI) is a devastating complication after joint replacement surgery, and making diagnosis is often far from obvious. Calprotectin was recently proposed as a promising synovial biomarker to detect PJI. To our knowledge, no comparative study exists between enzyme-linked immunosorbent assay (ELISA) and rapid calprotectin test (CalFAST). Our purpose was to compare these methods with leukocyte esterase (LE) test from synovial fluid of painful knee arthroplasty subjected to infectious workup., Methods: Ninety-three patients were included in this prospective observational study. They underwent synovial fluid aspiration that was analyzed for cell count, microbiological culture, LE test, calprotectin rapid test, and calprotectin immunoassay dosage. The 2018 Consensus Statements criteria for PJI were used to diagnose PJI. Sensitivity, specificity, positive and negative likelihood ratio, and receiver operating characteristic were calculated for detection methods and compared., Results: We categorized 39 patients as infected and 50 patients as not infected. The sensitivity comparing the ELISA test and CalFAST test was similar, 92.3% and 97.4%, respectively. LE rapid test showed 46% of sensitivity and 94% of specificity. The highest specificity was found with ELISA test (100%). Comparing the receiver operating characteristic curves by z-test, there were statistically significant differences between LE strip test and the other two methods. Otherwise, no statistically significant differences were present between ELISA and CalFAST test., Conclusion: Synovial calprotectin detection has high accuracy in knee PJI diagnosis, both ELISA and rapid test. LE strip test remains a good test to confirm the diagnosis of PJI in case of positivity. In clinical practice, the calprotectin rapid test can be considered an excellent point-of-care test., (Copyright © 2022 Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
14. Seroprevalence of SARS-CoV-2-Specific Antibodies in Cancer Patients Undergoing Active Systemic Treatment: A Single-Center Experience from the Marche Region, Italy.
- Author
-
Cantini L, Bastianelli L, Lupi A, Pinterpe G, Pecci F, Belletti G, Stoico R, Vitarelli F, Moretti M, Onori N, Giampieri R, Rocchi MBL, and Berardi R
- Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence in cancer patients may vary widely dependent on the geographic area and this has significant implications for oncological care. The aim of this observational, prospective study was to assess the seroprevalence of SARS-CoV-2 IgM/IgG antibodies in solid cancer patients referred to the academic institution of the Marche Region, Italy, between 1 July and 26 October 2020 and to determine the accuracy of the rapid serological test. After performing 3767 GCCOV-402a rapid serological tests on a total of 949 patients, seroconversion was initially observed in 13 patients (1.4%). Ten (77% of the total positive) were IgG-positive, 1 (8%) were IgM-positive and 2 (15%) IgM-positive/IgG-positive. However, only 7 out of 13 were confirmed as positive at the reference serological test (true positives), thus seroprevalence after cross-checking was 0.7%. No false negatives were reported. The kappa value of the consistency analysis was 0.71. Due to rapid serological test high false positive rate, its role in assessing seroconversion rate is limited, and the standard serological tests should remain the gold standard. However, as rapid test negative predictive value is high, GCCOV-402a may instead be useful to monitor patient immunity over time, thus helping to assist ongoing vaccination programs.
- Published
- 2021
- Full Text
- View/download PDF
15. Response to Letter to the Editor on "Synovial Fluid Calprotectin for the Preoperative Diagnosis of Chronic Periprosthetic Joint Infection".
- Author
-
Salari P, Grassi M, Cinti B, Onori N, and Gigante A
- Subjects
- Humans, Leukocyte L1 Antigen Complex, Synovial Fluid, Arthritis, Infectious, Arthroplasty, Replacement, Knee, Prosthesis-Related Infections diagnosis
- Published
- 2020
- Full Text
- View/download PDF
16. Synovial Fluid Calprotectin for the Preoperative Diagnosis of Chronic Periprosthetic Joint Infection.
- Author
-
Salari P, Grassi M, Cinti B, Onori N, and Gigante A
- Subjects
- Biomarkers, Humans, Leukocyte L1 Antigen Complex, Reproducibility of Results, Sensitivity and Specificity, Synovial Fluid metabolism, Prosthesis-Related Infections diagnosis, alpha-Defensins metabolism
- Abstract
Background: The diagnosis of periprosthetic joint infection (PJI) represents a challenge in clinical practice and the analysis of synovial fluid is a useful diagnostic tool. Calprotectin is an inflammatory biomarker widely used in the evaluation of chronic inflammatory diseases; however, little is known about its role in PJI. The purpose of this study is to determine the reliability of synovial calprotectin in the diagnosis of PJI., Methods: Seventy-six patients with painful knee arthroplasty were included in this prospective observational study. Synovial fluid was analyzed for cell count, percentage of polymorphonuclear neutrophils, microbiological culture, leukocyte esterase strip test, alpha-defensin rapid test, and calprotectin immunoassay dosage. The 2018 Consensus Statements criteria for PJI were used as standard reference to define the presence of infection. Sensitivity, specificity, positive and negative likelihood ratio, and receiver-operation characteristic curve were calculated for calprotectin immunoassay test., Results: By 2018 Consensus Statements criteria for PJI, 28 patients were considered infected, 44 patients were considered not infected, and 4 patients were classified as inconclusive. The calprotectin synovial fluid test resulted in 2 false-positive results and no false-negative results. The calprotectin synovial fluid test demonstrated a sensitivity of 100% (95% confidence interval [CI] 99.96-100) and specificity of 95% (95% CI 89.4-100) for the diagnosis of PJI. The positive likelihood ratio was 22 (95% CI 5.680-85.209) and the negative likelihood ratio was 0 (95% CI 0-0.292). The area under the receiver-operation characteristic curve was 0.996 (95% CI 94.3-100)., Conclusion: The present study suggests that synovial calprotectin immunoassay test has a high sensitivity and specificity in the diagnosis of knee PJI. Moreover, it is easily applied, quick and valuable in clinical practice., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
17. Pulse-mediated chemotherapy enhances local control and survival in a spontaneous canine model of primary mucosal melanoma.
- Author
-
Spugnini EP, Dragonetti E, Vincenzi B, Onori N, Citro G, and Baldi A
- Subjects
- Animals, Disease-Free Survival, Dogs, Electric Stimulation, Electroporation methods, Female, Male, Melanoma drug therapy, Melanoma mortality, Mouth Neoplasms drug therapy, Mouth Neoplasms mortality, Mucous Membrane drug effects, Mucous Membrane pathology, Survival Rate, Treatment Outcome, Bleomycin administration & dosage, Dog Diseases drug therapy, Electroporation veterinary, Melanoma veterinary, Mouth Neoplasms veterinary, Pulse Therapy, Drug veterinary
- Abstract
Mucosal melanomas account for 1% of all malignant melanomas in humans. Treatment options include surgery, chemotherapy, immunotherapy and radiation therapy; however, local recurrence and distant dissemination are still frequent. We treated locally aggressive spontaneous canine oral melanomas that, because of their advanced stage, were not treatable with conventional strategies. A cohort of 10 dogs with oral melanoma was enrolled over a 4-year period. The dogs received two sessions of local bleomycin, followed by the application of trains of biphasic pulses. The treatment was well tolerated and resulted in an overall response rate of 80% with 50% long-term control. Of interest, only one of the dogs died of metastatic disease, and four of the long-term survivors showed a vitiligo-like discoloration at the site of treatment, potentially suggesting a recruitment of the immune system by the therapy. Further studies are needed to characterize this approach and to determine its suitability for head and neck mucosal melanoma.
- Published
- 2006
- Full Text
- View/download PDF
18. Effects of indinavir in a preliminary phase I study on dogs with stage III slenic hemangiosarcoma.
- Author
-
Spugnini EP, Esposito V, Groeger AM, Cassandro R, Onori N, Chirianni A, and Baldi A
- Subjects
- Animals, Dog Diseases metabolism, Dogs, Fibroblast Growth Factor 2 biosynthesis, Hemangiosarcoma metabolism, Hemangiosarcoma veterinary, Splenic Neoplasms metabolism, Splenic Neoplasms veterinary, Vascular Endothelial Growth Factor A biosynthesis, Dog Diseases drug therapy, HIV Protease Inhibitors therapeutic use, Hemangiosarcoma drug therapy, Indinavir therapeutic use, Splenic Neoplasms drug therapy
- Abstract
HIV protease inhibitors are antiretroviral drugs able to prevent production of infectious particles. It has been shown that these protease inhibitors are able to inhibit cancer-promoted angiogenesis in patients affected by Kaposi's sarcoma. A preliminary phase I study on dogs with stage III splenic hemangiosarcoma was designed in order to evaluate the efficacy and toxicity of the protease inhibitor Indinavir to delay the progression of this advanced neoplasm. The results suggest that Indinavir is potentially beneficial in dogs affected by microscopic residual disease.
- Published
- 2006
19. Prevention of radiotherapy-induced emesis.
- Author
-
Tonini G, Vincenzi B, Santini D, La Cesa A, Finolezzi E, Onori N, D'Angelillo R, Baldi A, and Trodella L
- Subjects
- Antiemetics therapeutic use, Clinical Trials as Topic, Humans, Radionuclide Imaging, Radiotherapy Dosage, Risk Factors, Neoplasms radiotherapy, Radiotherapy adverse effects, Vomiting diagnostic imaging, Vomiting prevention & control
- Abstract
In this minireview the authors examine and discuss the radioprotective compounds and the new combination therapies for the prophylaxis of radiation-induced emesis. Radiation-induced emesis is an important secondary effect of this anticancer treatment and it represents one of the causes of therapy interruption and decay of life quality before the introduction of optimal control of radiation-induced emesis with new antiemetic drugs which ensure the continuance of radiotherapy and avoid time breaks, that could negatively influence the efficacy of anticancer treatment. The incidence, the severity or the latency of radiotherapy-induced nausea and vomiting are correlated both with the treatment features (fractions, total dose, irradiation site) and with the main clinical characteristics of the patients. In contrast to the very extensive literature on the prevention of chemotherapy-induced emesis, relatively few studies about the prevention of nausea and vomiting in patients submitted to radiotherapy have been published. Among antiemetic drugs for the prevention of emesis, benzamides and in particular metoclopramide, are widely used in clinical practice. The introduction of selective 5-HT3 antagonists in clinical practice produced an important improvement in control of chemotherapy induced emesis, but few published studies were aimed at evaluating the efficacy of these drugs in the prophylaxis of nausea and vomiting due to radiation exposure. We herewith present a brief summary of Clinical practice guidelines for the use of antiemetics in anticancer therapy recently published by ASCO (American Society of Clinical Oncology).
- Published
- 2003
20. Apelin expression in normal human tissues.
- Author
-
De Falco M, De Luca L, Onori N, Cavallotti I, Artigiano F, Esposito V, De Luca B, Laforgia V, Groeger AM, and De Luca A
- Subjects
- Apelin, Female, Humans, Immunohistochemistry, Intercellular Signaling Peptides and Proteins, Ligands, Tissue Distribution, Carrier Proteins metabolism, Organ Specificity
- Abstract
Apelin is an endogenous ligand of the human orphan receptor APJ (orphan G protein-coupled receptor). This peptide is produced through processing from the C-terminal portion in the pre-proprotein consisting of 77 amino acid residues and exists in multiple molecular forms. Although the main physiological functions of apelin have not been clarified yet, it has been demonstrated that apelin partially suppresses cytokine production from mouse spleen and, specifically, induces the promotion of extracellular acidification and inhibition of cAMP production in Chinese hamster ovary cells. Moreover, it is involved in the regulation of blood pressure and blood flow. In this study we have analyzed, by immunohistochemistry, apelin distribution in several human tissues, demonstrating that apelin has a widespread pattern of expression. These results seem to confirm that apelin functions widely in various tissues interacting with its specific receptor APJ.
- Published
- 2002
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.